Analyst Gil Blum of Needham maintained a Buy rating on I-MAB, boosting the price target to $6.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gil Blum has given his Buy rating due to a combination of factors that suggest a positive outlook for I-MAB. The company’s recent financing has alleviated concerns regarding financial stability, allowing for an increase in the target price to $6. This financial boost is expected to support operations through the fourth quarter of 2028, providing a solid foundation for future developments.
Additionally, the promising results from the dose escalation study involving Givastomig, nivolumab, and chemotherapy in first-line gastric cancer patients indicate potential efficacy across a wide range of biomarker expressions. The upcoming dose expansion results, expected in the first quarter of 2026, are anticipated to guide the next steps for the program, with a randomized Phase II trial on the horizon. These developments, coupled with the forthcoming monotherapy results, underscore the potential for I-MAB’s pipeline, justifying the Buy rating.
Blum covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Rocket Pharmaceuticals, and Taysha Gene Therapies. According to TipRanks, Blum has an average return of -1.5% and a 37.47% success rate on recommended stocks.